How Ebola Stocks Are Responding After the Outbreak in the Congo
The WHO has confirmed a new outbreak of the Ebola virus in the Democratic Republic of Congo. A few of the Ebola-related stocks are responding.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
[cnxvideo id=”655426″ placement=”ros”]The World Health Organization (WHO) has confirmed a new outbreak of the Ebola virus in the Democratic Republic of Congo. So far at least one person has died after contracting the virus, in a lab-confirmed case. This is the first time in a while that the virus has resurfaced, and a few of the Ebola-related stocks are responding.
In the last major outbreak between 2014 and 2015, over 11,000 people died in West Africa, mainly in Guinea, Sierra Leone and Liberia.
24/7 Wall St. has taken a quick look at a few stocks that have an Ebola treatment in their portfolio or deal directly with the virus. We have included a recent trading history, as well as some color and the consensus analyst price target.
Sarepta Therapeutics Inc. (NASDAQ: SRPT) saw its shares up 1.5% at $34.02, with a consensus analyst price target of $60.88 and a 52-week trading range of $14.83 to $63.73. Year to date, shares are up 22%.
[nativounit]
Lakeland Industries Inc. (NASDAQ: LAKE) shares are up over 8% at $11.94. The stock has a 52-week range of $8.00 to $11.95 and a consensus price target of $15.00. So far in 2017, excluding Friday’s move, the stock is up nearly 6%.
Novavax Inc. (NASDAQ: NVAX) shares are up 1% at $0.94, with a consensus price target of $3.48 and a 52-week range of $0.73 to $8.49. Year to date, the stock is down 26%.
NewLink Genetics Corp. (NASDAQ: NLNK) saw its stock jump 3.6% to $17.45, within a 52-week range of $9.41 to $25.17 and with a consensus price target of $26.80. In 2017, the stock is up 63%.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares are up nearly 1% at $90.16. The stock has a 52-week range of $73.45 to $102.49. Year to date, the stock is up about 8%.
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
